May 19, 2023
2 min watch
Save
VIDEO: Promising results reported for cell therapy in corneal endothelial disease
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Key takeaways:
- The treatment was recently approved in Japan.
- U.S. clinical trials are expected to begin later this year.
SAN DIEGO — In this Healio Video Perspective from Eyecelerator@ASCRS, Greg Kunst, CEO of Aurion Biotech, discusses data from the Escalon clinical trial.
The trial evaluated the company’s cell therapy targeting corneal endothelial disease.
“These results are remarkable,” Kunst said. “We’ve been able to demonstrate at 12 months that not only can we reduce central corneal thickness back to healthy levels, but more importantly, more than 90% of patients were able to see an improvement in vision of three lines or greater.”
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Kunst reports being the CEO of Aurion Biotech.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.